Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GlobeImmune, Inc. (GBIM)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
1450 Infinite Drive 80027
Louisville, CO, US
Louisville, CO, US
CEO
Donald Bellgrau
Website
globeimmune.com
IPO
2014-07-02
CIK 1245104 ISIN US37957B1008
Description
GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline includes several key candidates: For infectious diseases: GS-4774 is currently in Phase 2 clinical trials, designed to treat individuals chronically infected with the hepatitis B virus who are also on oral antiviral suppressive therapy. Additionally, GlobeImmune has various other infectious disease programs in the preclinical stage, such as GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infections. For oncology: GlobeImmune is advancing GI-6301, which targets cancers characterized by the expression of the brachyury protein. GI-6207 is progressing through Phase 2 clinical trials for medullary thyroid cancer. Furthermore, GI-4000 is a significant asset, undergoing Phase 2b clinical trials for resected pancreatic cancer, and is also in separate Phase 2 trials for non-small cell lung cancer and colorectal cancer. To support its endeavors, GlobeImmune maintains strategic alliances with industry leaders such as Gilead Sciences, Inc. and Celgene Corporation.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
548
Beta
-200.46
Float Shares
4.37M
Free Float %
76.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -50.00% | -50.00% | -99.99% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-31.84
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+8.2% ★ Q1'16: -20.6% (vs Q1'15)
-
EPS growth Biotechnology: +29.7%+93.1% ★ Q1'16: +44.4% (vs Q1'15)
-
FCF margin FCF growth · Biotechnology: +16.2%-110.8% Q1'16: -128.0% (vs Q1'15)
-
EBIT margin Biotechnology: +0.0%-42.9% Q1'16: -91.5% (vs Q1'15)
-
ROIC Biotechnology: -16.1%— Q1'16: +52.7% (vs Q1'15)
-
Share dilution Biotechnology: -3.4%+97.3% Q1'16: +0.0% (vs Q1'15)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'16: 0.00× (vs Q1'15)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.86M
OE per share TTM
-0.99
Owner's Yield
-1,018,311.92%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
12.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BVF Inc. | 678.4K | 11.80% | — | 678.4K | — | — | CO | Delaware | 2015-06-05 | ↗ |
| 2 | BVF Partners L.P. | 678.4K | 11.80% | — | 678.4K | — | — | IA, PN | Delaware | 2015-06-05 | ↗ |
| 3 | Mark N. Lampert | 678.4K | 11.80% | — | 678.4K | — | — | IN | United States | 2015-06-05 | ↗ |
| 4 | Augustine Lawlor | 593.2K | 10.30% | — | 593.2K | — | — | IN | USA | 2014-07-17 | ↗ |
| 5 | Christopher Mirabelli, Ph.D. | 593.2K | 10.30% | — | 593.2K | — | — | IN | USA | 2014-07-17 | ↗ |
| 6 | Harold R. Werner | 593.2K | 10.30% | — | 593.2K | — | — | IN | USA | 2014-07-17 | ↗ |
| 7 | HealthCare Partners VII, L.P. | 593.2K | 10.30% | — | 593.2K | — | — | PN | Delaware | 2014-07-17 | ↗ |
| 8 | HealthCare Ventures VII, L.P. | 593.2K | 10.30% | — | 593.2K | — | — | PN | Delaware | 2014-07-17 | ↗ |
| 9 | James H. Cavanaugh, Ph.D. | 593.2K | 10.30% | — | 593.2K | — | — | IN | USA | 2014-07-17 | ↗ |
| 10 | John W. Littlechild | 593.2K | 10.30% | — | 593.2K | — | — | IN | USA | 2014-07-17 | ↗ |
| 11 | S Gary J. Morgenthaler (“Morgenthaler”) | 539.3K | 9.40% | — | 539.3K | — | — | IN | United States | 2014-07-11 | ↗ |
| 12 | S Gary R. Little (“Little”) | 539.3K | 9.40% | — | 539.3K | — | — | IN | United States | 2014-07-11 | ↗ |
| 13 | S James W. Broderick (“Broderick”) | 539.3K | 9.40% | — | 539.3K | — | — | IN | United States | 2014-07-11 | ↗ |
| 14 | S John D. Lutsi (“Lutsi”) | 539.3K | 9.40% | — | 539.3K | — | — | IN | United States | 2014-07-11 | ↗ |
| 15 | S Morgenthaler Management Partners VII, LLC (“Morgenthaler VII GP”) | 539.3K | 9.40% | 539.3K | 539.3K | 539.3K | — | OO | Delaware | 2014-07-11 | ↗ |
| 16 | S Morgenthaler Partners VII, L.P. (“Morgenthaler VII”) | 539.3K | 9.40% | 539.3K | 539.3K | 539.3K | — | PN | Delaware | 2014-07-11 | ↗ |
| 17 | S Peter G. Taft (“Taft”) | 539.3K | 9.40% | — | 539.3K | — | — | IN | United States | 2014-07-11 | ↗ |
| 18 | S Robert C. Bellas, Jr. (“Bellas”) | 539.3K | 9.40% | — | 539.3K | — | — | IN | United States | 2014-07-11 | ↗ |
| 19 | S Robert D. Pavey (“Pavey”) | 539.3K | 9.40% | — | 539.3K | — | — | IN | United States | 2014-07-11 | ↗ |
| 20 | Biotechnology Value Fund, L.P. | 330.9K | 5.80% | — | 330.9K | — | — | PN | Delaware | 2015-06-05 | ↗ |
| 21 | Jeffrey Wm. Bartelt | 300.2K | 5.20% | 300.2K | — | 300.2K | — | IN | U.S. Citizen | 2016-02-24 | ↗ |
| 22 | Biotechnology Value Fund II, L.P. | 190.0K | 3.30% | — | 190.0K | — | — | PN | Delaware | 2015-06-05 | ↗ |
| 23 | MSI BVF SPV, LLC | 96.7K | 1.70% | — | 96.7K | — | — | OO | Delaware | 2015-06-05 | ↗ |
| 24 | Investment 10, L.L.C. | 60.7K | 1.10% | — | 60.7K | — | — | OO | Illinois | 2015-06-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
1.6K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,614
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-03-17 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 12,468 | 1.52 | 19.0K | 65,958 | — | ↗ |
| 2016-03-16 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 8,862 | 1.85 | 16.4K | 78,426 | — | ↗ |
| 2016-03-15 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 50,831 | 2.17 | 110.2K | 87,288 | — | ↗ |
| 2016-03-11 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 76,662 | 2.32 | 177.5K | 138,119 | — | ↗ |
| 2016-03-10 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 127 | 1.16 | 147.15 | 3,882 | — | ↗ |
| 2016-03-09 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 157 | 1.21 | 189.83 | 4,009 | — | ↗ |
| 2016-03-08 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 5,741 | 1.14 | 6.5K | 224,997 | — | ↗ |
| 2016-03-07 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 100 | 1.07 | 107.26 | 4,325 | — | ↗ |
| 2016-03-04 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 176 | 1.02 | 179.19 | 4,425 | — | ↗ |
| 2016-03-03 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 46 | 1.12 | 51.49 | 4,601 | — | ↗ |
| 2016-03-02 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 5,471 | 1.17 | 6.4K | 242,336 | — | ↗ |
| 2016-03-01 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 8,561 | 0.96 | 8.2K | 247,807 | — | ↗ |
| 2016-02-29 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 2,919 | 0.95 | 2.8K | 256,368 | — | ↗ |
| 2016-02-26 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 6,520 | 0.95 | 6.2K | 259,287 | — | ↗ |
| 2016-02-25 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 2,003 | 1.06 | 2.1K | 265,807 | — | ↗ |
| 2016-02-24 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 3,640 | 1.17 | 4.3K | 267,810 | — | ↗ |
| 2016-02-23 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 2,627 | 1.36 | 3.6K | 271,450 | — | ↗ |
| 2016-02-22 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 5,643 | 1.43 | 8.0K | 274,077 | — | ↗ |
| 2016-02-19 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 13,970 | 1.43 | 20.0K | 279,720 | — | ↗ |
| 2016-02-19 | HEALTHCARE VENTURES VII LP | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.39 | 7.0K | 554,267 | — | ↗ |
| 2016-02-18 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 11,600 | 1.42 | 16.4K | 293,690 | — | ↗ |
| 2016-02-18 | HEALTHCARE VENTURES VII LP | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.40 | 7.0K | 559,267 | — | ↗ |
| 2016-02-17 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 7,720 | 1.47 | 11.4K | 305,290 | — | ↗ |
| 2016-02-17 | HEALTHCARE VENTURES VII LP | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.53 | 7.7K | 564,267 | — | ↗ |
| 2016-02-16 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 1,986 | 1.50 | 3.0K | 313,010 | — | ↗ |
| 2016-02-16 | HEALTHCARE VENTURES VII LP | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.51 | 7.6K | 569,267 | — | ↗ |
| 2016-02-12 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 34 | 1.59 | 54.05 | 6,665 | — | ↗ |
| 2016-02-12 | HEALTHCARE VENTURES VII LP | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.59 | 8.0K | 574,267 | — | ↗ |
| 2016-02-11 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 32 | 1.72 | 55.13 | 6,699 | — | ↗ |
| 2016-02-11 | HEALTHCARE VENTURES VII LP | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.72 | 8.6K | 579,267 | — | ↗ |
| 2016-02-10 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 1,168 | 1.93 | 2.3K | 317,375 | — | ↗ |
| 2016-02-09 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 2,724 | 1.99 | 5.4K | 318,543 | — | ↗ |
| 2016-02-08 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 3,113 | 2.01 | 6.2K | 321,267 | — | ↗ |
| 2016-02-05 | MITCHELL DANIEL J | Director | S-Sale | D | Common Stock | 1,265 | 2.28 | 2.9K | 324,380 | — | ↗ |
| 2015-07-09 | MITCHELL DANIEL J | Director | A-Award | A | Stock Option (right to buy) | 1,697 | 2.56 | 4.3K | 1,697 | — | ↗ |
| 2015-04-10 | RODELL TIMOTHY C JR | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 1,904 | — | ↗ |
| 2015-01-06 | RODELL TIMOTHY C JR | Director / Officer | A-Award | A | Stock Option (right to buy) | 39,480 | 7.71 | 304.4K | 39,480 | — | ↗ |
| 2014-07-08 | Torres S. Edward | Director | C-Conversion | A | Warrant to Purchase Common Stock (right to buy) | 1,614 | 0.00 | — | 1,614 | — | ↗ |
| 2014-07-08 | RODELL TIMOTHY C JR | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 10.00 | 50.0K | 5,000 | — | ↗ |
| 2014-07-08 | MORGENTHALER PARTNERS VII LP | 10% Owner | C-Conversion | D | Warrant to Purchase Series B Preferred Stock (right to buy) | 162,369 | 0.00 | — | 0 | — | ↗ |
| 2014-07-08 | MITCHELL DANIEL J | Director | C-Conversion | A | Warrant to Purchase Common Stock (right to buy) | 74 | 42.00 | 3.1K | 74 | — | ↗ |
| 2014-07-08 | HEALTHCARE VENTURES VII LP | 10% Owner | C-Conversion | D | Series B Convertible Preferred Stock | 5,904,335 | 0.00 | — | 0 | — | ↗ |
| 2014-07-08 | Celgene International Inc | 10% Owner | C-Conversion | A | Common Stock | 56,256 | 0.00 | — | 400,670 | — | ↗ |
| 2014-07-01 | RODELL TIMOTHY C JR | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 1,094 | — | ↗ |
| 2014-07-01 | MORGENTHALER PARTNERS VII LP | 10% Owner | — | D | Series C Convertible Preferred Stock | 3,879,015 | 0.00 | — | 0 | — | ↗ |
| 2014-07-01 | MITCHELL DANIEL J | Director | — | I | Warrant to Purchase Series C Preferred Stock (right to buy) | 66,955 | 1.45 | 96.7K | 0 | — | ↗ |
| 2014-07-01 | HEALTHCARE VENTURES VII LP | 10% Owner | — | I | Warrant to Purchase Series C Convertible Preferred Stock | 116,586 | 1.45 | 168.5K | 0 | — | ↗ |
| 2014-07-01 | Celgene International Inc | 10% Owner | — | D | Series C Convertible Preferred Stock | 2,160,682 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-1.38M
Shares Outstanding
5.75M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Donald Bellgrau | Scientific Founder & Chairman of The Scientific Advisory Board | — | — |
ESG Rating
ESG Score History
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GBIM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
